¡Ya estamos en ! Descubre más
CYAD

Celyad Oncology SA American Depositary Shares

Excluida de cotización

CYAD dejó de cotizar en bolsa el 18 de mayo de 2023.

 

Acerca de: Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.

Empleados: 39

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 0%
Neutral 0%
Negativo 0%

No hemos recibido artículos de noticias recientes sobre CYAD.

Gráficos de precios implementados con Lightweight Charts™